Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.59 |
| ▸ | CTSL | P07711 | 1/20 | 0.57 |
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.51 |
| ▸ | FURIN | P09958 | 4/20 | 0.50 |
| ▸ | NMT2 | O60551 | 2/20 | 0.48 |
| ▸ | NMT1 | P30419 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL27081431 | 1.00 | SLC6A5 (0.59) | SLC6A5CTSLNOD1FURINNMT2 | |
| SCHEMBL443317 | 0.94 | SLC6A5 (0.66) | SLC6A5CTSLNOD1FURINNMT2 | |
| SCHEMBL445569 | 0.94 | SLC6A5 (0.66) | SLC6A5CTSLNOD1FURINNMT2 | |
| SCHEMBL29520919 | 0.92 | SLC6A5 (0.64) | SLC6A5CTSLNOD1FURINNMT2 | |
| Acetic Acid SCHEMBL30391850 | 0.92 | SLC6A5 (0.64) | SLC6A5CTSLNOD1FURINNMT2 | |
| Acetic Acid SCHEMBL25220206 | 0.92 | SLC6A5 (0.64) | SLC6A5CTSLNOD1FURINNMT2 | |
| SCHEMBL30496949 | 0.89 | SLC6A5 (0.68) | SLC6A5CTSLNOD1FURINNMT2 | |
| SCHEMBL30496969 | 0.89 | SLC6A5 (0.68) | SLC6A5CTSLNOD1FURINNMT2 | |
| SCHEMBL29640336 | 0.89 | SLC6A5 (0.68) | SLC6A5CTSLNOD1FURINNMT2 | |
| SCHEMBL29640314 | 0.89 | SLC6A5 (0.68) | SLC6A5CTSLNOD1FURINNMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013142251-A1 | CYCLODEXTRIN-BASED MICROEMULSIONS, AND DERMATOLOGICAL USES THEREOF | PRECISION DERMATOLOGY, INC. (US) | 2013-09-26 | — | — | WO | claimed |
| US-20130251644-A1 | Cyclodextrin-Based Microemulsions, and Dermatological Uses Thereof | PRECISION DERMATOLOGY, INC. (US) | 2013-09-26 | — | — | US | claimed |
| EP-4509174-A2 | COMPOSITIONS AND METHODS FOR PROMOTING SKIN HEALTH | The Regents of the University of California (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20250017954-A1 | Formulations and Methods for Treating Symptoms of Menopause | Kindra Corporation (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4433045-A2 | FORMULATIONS AND METHODS FOR TREATING SYMPTOMS OF MENOPAUSE | KINDRA CORPORATION (US) | 2024-09-25 | — | — | EP | disclosed |
| EP-3411011-B1 | COMPOSITIONS AND METHODS FOR PROMOTING SKIN HEALTH | UNIV CALIFORNIA (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-118510501-A | Formulations and methods for treating climacteric symptoms | 金卓拉公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2023091628-A2 | FORMULATIONS AND METHODS FOR TREATING SYMPTOMS OF MENOPAUSE | PG13 LAUNCHPAD ALPHA, INC. DBA KINDRA (US) | 2023-05-25 | — | — | WO | disclosed |
| US-11351116-B2 | Compositions and methods for treating skin conditions | AQUA REGENERATIVE THERAPIES LLC | 2022-06-07 | — | — | US | disclosed |
| US-20210137997-A1 | COMPOSITIONS AND METHODS FOR PROMOTING SKIN HEALTH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-13 | — | — | US | disclosed |
| US-20190030090-A1 | COMPOSITIONS AND METHODS FOR PROMOTING SKIN HEALTH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-31 | — | — | US | disclosed |
| US-20130253015-A1 | Cyclodextrin-Based Microemulsions, and Dermatological Uses Thereof | PRECISION DERMATOLOGY, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130251644-A1 | Cyclodextrin-Based Microemulsions, and Dermatological Uses Thereof | PRECISION DERMATOLOGY, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2013142251-A1 | CYCLODEXTRIN-BASED MICROEMULSIONS, AND DERMATOLOGICAL USES THEREOF | PRECISION DERMATOLOGY, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| US-20130253014-A1 | Cyclodextrin-Based Microemulsions, and Dermatological Uses Thereof | PRECISION DERMATOLOGY, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2013142249-A1 | CYCLODEXTRIN-BASED MICROEMULSIONS, AND DERMATOLOGICAL USES THEREOF | PRECISION DERMATOLOGY, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013142247-A1 | CYCLODEXTRIN-BASED MICROEMULSIONS, AND DERMATOLOGICAL USES THEREOF | PRECISION DERMATOLOGY, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| US-20100136103-A1 | COSMETIC ANTI-AGEING SKIN CARE COMPOSITIONS | TUPPERWARE PRODUCTS S.A. (CH) | 2010-06-03 | — | — | US | disclosed |
| EP-1992332-A1 | Cosmetic anti ageing skin care compositions | Tupperware Products S.A. (CH) | 2008-11-19 | — | — | EP | disclosed |
| EP-1790330-A2 | Cosmetic and dermatological compositions containing oligopeptides and apple extract | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136103-A1 | COSMETIC ANTI-AGEING SKIN CARE COMPOSITIONS | CUTA, COL14A1, CTSA | SLC6A5 2372/4885CTSL 686/4885NOD1 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.